438
Registered trials
168
Recruiting
232
Completed trials
188
Sponsors
25
Countries
Phase III:
156
Phase II/III:
21
Phase II:
168
Phase I/II:
43
Phase III/IV:
3
Phase IV:
12
Phase I:
3
Phase I (Other):
2
Phase I (FiH):
29
Other:
1
Oversight events:
9 serious breaches
62 temporary halts
7 urgent safety measures
13 unexpected events
14 corrective measures
across 47 trials
View oversight register →
Indications tested
Non-small cell lung cancer
39
Non-small cell lung cancer metastatic
28
Triple negative breast cancer
14
Squamous cell carcinoma of head and neck
12
Non-small cell lung cancer stage IV
11
Non-small cell lung cancer stage IIIB
10
Malignant melanoma
7
Colorectal cancer metastatic
6
Ovarian cancer
5
Metastatic renal cell carcinoma
5
Non-small cell lung cancer stage IIIA
5
Malignant melanoma stage III
5
Sponsors using this IMP
Merck Sharp & Dohme LLC
116
AstraZeneca AB
12
Genmab A/S
9
Unicancer
9
Bristol-Myers Squibb Services Unlimited Company
6
Pfizer Inc.
6
Daiichi Sankyo Inc.
5
Fondazione IRCCS Istituto Nazionale Dei Tumori
5
Gilead Sciences Inc.
5
Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting
5
Institut Gustave Roussy
5
Seagen Inc.
5
All trials
438 total-
HARMONi-3 Not authorised
Showing 1–24 of 438 trials